HLA-01:03 Allele in Lung Transplant Recipients Correlates with Higher Chronic Lung Allograft Dysfunction Occurrence

Table 2

Baseline comparison of distribution and risk factors for 119 patients who underwent LTx according to HLA-E genotypes.

	E01:01/01:01	E01:01/01:03	E01:03/01:03	p	01:01/01:01	E01:03 allele	p
Genotypes frequency (, %)	38 (31.9)	57 (47.9)	24 (20.2)		38 (31.9)	81 (68.1)
Male (, %)	15 (40)	28 (49)	12 (50)	0.60	15 (39.5)	40 (49)	0.33
Age of recipient (SD)	39.1 (14.2)	40.23 (13)	39.6 (12)	0.92	39.1 (14.2)	40 (13)	0.72
Initial disease				0.33			0.91
Emphysema (, %)	10 (26.3)	11 (19.3)	10 (41.7)		10 (26.3)	21 (25.9)
Fibrosis (, %)	8 (21.1)	8 (14)	5 (20.8)		8 (21.1)	13 (16.1)
Cystic fibrosis (, %)	14 (36.8)	28 (49.1%)	6 (25%)		14 (36.8)	34 (42.1)
Others (, %)	6 (15.8)	10 (17.5%)	3 (12.5)		6 (15.8)	13 (16)
Transplant procedure				0.58			0.92
Lung and heart transplantation (, %)	1 (2.6)	0 (0)	1 (4.2)		1 (2.6)	1 (1.2)
Single lung transplantation (, %)	8 (21.1)	14 (24.6)	4 (16.7)		8 (21.1)	18 (22.2)
Bilateral lung transplantation (, %)	29 (76.3)	43 (75.4)	19 (79.2)		29 (76.3)	62 (76.5)
CMV status
D+/R− (, %)	6 (16.2)	7 (12.3)	4 (17.4)	0.83	6 (16.2)	11 (13.8)	0.78
D+/R+ or − (, %)	19 (51)	31 (54)	9 (40)	0.46	19 (51)	40 (50)	0.88
D+ or −/R+ (, %)	22 (58)	36 (63)	12 (50)	0.54	22 (58)	48 (59)	0.88
Mismatch HLA/6 ()	5.03	5	4.83	0.9	5.03	4.95	0.90
Infection at M1 (, %)	8 (53.3)	16 (47.1%)	2 (25)	0.49	8 (53.3)	18 (42.9)	0.48
Infection at M3 (, %)	6 (46.2)	7 (38.9)	5 (50)	0.83	6 (46.2)	12 (42.9)	0.84
Infection in first year (, %)	16 (42)	32 (56)	11 (45.8)	0.37	16 (42.1)	43 (53.1)	0.26
DSA at M1 (, %)	7 (63.6)	13 (81.3)	5 (83.3)	0.51	7 (63.5)	18 (81.8)	0.25
DSA at M3 (, %)	6 (66.7)	8 (66)	3 (60)	1	6 (66.7)	11 (64.7)	0.92
CLAD occurrence (, %)	5 (22.7)	20 (40.8)	7 (58.3)	0.06	5 (22.7)	27 (44.3)	0.02
BOS (, %)	5 (23.8)	16 (32.7)	6 (22.2)	0.31	5 (23.8)	22 (36.1)	0.02
RAS (, %)	0 (0)	4 (8.2)	1 (8.3)	0.41	0 (0)	5 (8.2)	0.32
Overall survival (median, year)	2.37	3.7	2.6	0.01